Item 1.01 Entry into a Material Definitive Agreement
Private Placement and Securities Purchase Agreement
On March 22, 2017, Alphatec Holdings, Inc. (the Company) entered into a securities purchase agreement (the Purchase
Agreement) with certain institutional and accredited investors (collectively, the Purchasers), including certain directors and executive officers of the Company, providing for the sale by the Company of 1,809,628 shares (the
Common Shares) of its common stock (the Common Stock) at a purchase price of $2.00 per share, 15,245 shares (the Preferred Shares, and together with the Common Shares, the Shares) of newly designated
Series A Convertible Preferred Stock (the Series A Convertible Preferred Stock) at a purchase price of $1,000 per share (which Preferred Shares are convertible into approximately 7,622,372 shares of Common Stock, subject to
limitations on conversion until the approval by the Companys stockholders (Stockholder Approval) as required in accordance with the NASDAQ Global Select Market rules as further described below), and warrants to purchase up to
9,432,000 shares of its Common Stock at an exercise price of $2.00 per share (the Warrants), in a private placement (the Private Placement). The Warrants will become exercisable following Stockholder Approval, are
subject to certain ownership limitations, and expire five years after the date of such Stockholder approval.
The aggregate gross proceeds
for the Private Placement will be approximately $18.9 million. The Company intends to use the net proceeds from the Private Placement for general corporate and working capital purposes. The Private Placement is expected to close on or about
March 28, 2017 (the Closing), subject to the satisfaction of customary closing conditions.
Certain directors and
executive officers of the Company agreed to purchase an aggregate of $2.35 million of shares of Series A Convertible Preferred Stock, which shares are convertible into approximately 1,175,000 shares of Common Stock, and Warrants to
purchase up to 1,175,000 shares of Common Stock.
Pursuant to the terms of the Purchase Agreement, from the Closing until the later
of 90 days after the effective date of the Resale Registration Statement (as defined below) or the date of Stockholder Approval, the Company is prohibited from issuing, or entering into any agreement to issue, or announcing the issuance or proposed
issuance of, any shares of Common Stock or Common Stock equivalents, subject to certain permitted exceptions.
The Private Placement is
exempt from the registration requirements of the Securities Act of 1933, as amended (the Securities Act) pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the
Securities Act and Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. Each of the Purchasers represented that it is an accredited investor within the meaning of Rule 501(a) of Regulation
D, and was acquiring the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The securities were offered without any general solicitation by the Company or its
representatives.
The securities sold and issued in the Private Placement will not be registered under the Securities Act or any state
securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the SEC) or an applicable exemption from the registration requirements.
Series A Convertible Preferred Stock
A
total of 15,245 shares of Series A Convertible Preferred Stock will be authorized for issuance under a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of the Company (the
Certificate of Designation), to be filed with the Secretary of State of the State of Delaware in connection with the Closing. The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be
convertible into approximately 500 shares of the Companys Common Stock. Until the date that Stockholder Approval is obtained, the Certificate of Designation limits the number of shares of Common Stock issuable upon conversion of the
Series A Convertible Preferred Stock such that, when aggregated with the shares of Common Stock issued at the Closing, such issuances shall not exceed 19.99% of the Companys issued and
outstanding Common Stock, as required by the rules and regulations of the NASDAQ Global Select Market. In addition, the Companys directors and officers will be unable to convert shares of
Series A Convertible Preferred Stock until Stockholder Approval is obtained, pursuant to the NASDAQ Global Select Market rules.
The
Series A Convertible Preferred Stock will be entitled to dividends on an
as-if-converted
basis in the same form as any dividends actually paid on shares of Common Stock
or other securities.
Shares of a holder of Series A Convertible Preferred Stock shall not be converted if, after giving effect to the
conversion, such holder and its affiliated persons would own beneficially more than 4.99% of the Common Stock (subject to adjustment up to 9.99% solely at the holders discretion upon 61 days prior notice to the Company or, solely as to a
holder, if such limitation is waived by such holder upon execution of the Purchase Agreement). The initial conversion price of $2.00 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or
other recapitalization affecting the Common Stock. In addition, for a period ending on the earlier of one year from effective date of the Resale Registration Statement or the date on which there are no shares of Series A Convertible Preferred Stock
outstanding, the conversion price is also subject to full ratchet anti-dilution protection in the event the Company issues securities at an effective price less than the initial conversion price, subject to certain exceptions.
Pursuant to the NASDAQ Global Select Market rules, holders of Series A Convertible Preferred Stock will not be entitled to cast votes as to
the approval of the conversion feature with respect to any shares of Common Stock purchased under the Purchase Agreement. If the Companys stockholders do not approve the conversion feature of the Series A Convertible Preferred Stock, the
shares of Series A Convertible Preferred Stock will not become convertible, and will remain outstanding in accordance with the terms of the Certificate of Designation.
Except as otherwise required by law, the holders of Series A Convertible Preferred Stock will have no right to vote on matters submitted to a
vote of the Companys stockholders. Without the prior written consent of 75% of the outstanding shares of Series A Convertible Preferred Stock, however, the Company may not: (a) alter or change adversely the powers, preferences or rights
given to the Preferred Stock or alter or amend the Certificate of Designation, (b) amend the Companys certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A
Convertible Preferred Stock, (c) increase the number of authorized shares of Series A Convertible Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.
In the event of the dissolution and winding up of the Company, the proceeds available for distribution to the Companys stockholders
shall be distributed pari passu among the holders of the shares of Common Stock and Series A Convertible Preferred Stock, pro rata based upon the number of shares held by each such holder, as if the outstanding shares of Series A Convertible
Preferred Stock were convertible, and were converted, into shares of Common Stock.
Registration Rights Agreement
In connection with the Private Placement, the Company agreed to enter into a registration rights agreement (the Registration Rights
Agreement) with the Purchasers, to be effective as of the Closing. Pursuant to the Registration Rights Agreement, the Company agreed to prepare and file a registration statement (the Resale Registration Statement) with the SEC
within 30 days after the Closing for purposes of registering the resale of the Common Shares, the shares of Common Stock issuable upon conversion of the Preferred Shares, and the shares of Common Stock issuable upon exercise of the Warrants.
The Company also agreed to use its reasonable best efforts to cause this registration statement to be declared effective by the SEC within 60 days after the Closing (90 days in the event the registration statement is reviewed by the SEC). If the
Company fails to meet the specified filing deadlines or keep the Resale Registration Statement effective, subject to certain permitted exceptions, the Company will be required to pay liquidated damages to the Purchasers. The Company also agreed,
among other things, to indemnify the selling holders under the registration statements from certain liabilities and to pay all fees and expenses incident to the Companys performance of or compliance with the Registration Rights Agreement.
Support Agreements
Prior to and as a condition for the Closing, certain stockholders of the Company will enter into support agreements (the Support
Agreements), pursuant to which such stockholders will agree to vote all shares of Common Stock owned by them in favor of transactions contemplated by the Purchase Agreement. The Support Agreements will terminate on the earlier of (i) the
termination of the Purchase Agreement pursuant to its terms or (ii) the date that is five days following the stockholders meeting at which Stockholder Approval is obtained.
Engagement Letter
The Company also
entered into an engagement letter (the Engagement Letter) on March 1, 2017 with H.C. Wainwright & Co., LLC (Wainwright), pursuant to which Wainwright agreed to serve as exclusive placement agent for the issuance
and sale of the securities in the Private Placement. The Company has agreed to pay Wainwright an aggregate fee equal to 7% of the gross proceeds received by the Company from the sale of the securities in the transaction; provided, however, that such
fee will be reduced to 3.5% of the gross proceeds received by the Company from the sale of the securities in the Private Placement made to the Companys officers and directors and their affiliates. Pursuant to the Engagement Letter, the Company
also agreed to grant to Wainwright or its designees warrants to purchase up to 5% of the aggregate number of shares sold in the Private Placement (the Wainwright Warrants). The Engagement Letter has a six month tail and right of first
offer period, indemnity and other customary provisions for transactions of this nature. The Wainwright Warrants have substantially the same terms as the Warrants, except that the Wainwright Warrants will have an exercise price equal to 125% of the
exercise price of the Warrants. The Wainwright Warrants and the shares issuable upon exercise of the Wainwright Warrants will be issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act as
transactions not involving a public offering and in reliance on similar exemptions under applicable state laws. The Company will also pay Wainwright a reimbursement for
non-accountable
expenses, including
legal fees and expenses of the placement agent in an amount up to $65,000.
Transaction Documents
The representations, warranties and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to the
Purchase Agreement and may be subject to limitations agreed upon by the contracting parties. In addition, such representations, warranties and covenants (i) are intended as a way of allocating the risk between the parties to the Purchase
Agreement and not as statements of fact, and (ii) may apply standards of materiality in a way that is different from what may be viewed as material by stockholders of, or other investors in, the Company. Accordingly, the Purchase Agreement is
filed with this report only to provide investors with information regarding the terms of transaction, and not to provide investors with any other factual information regarding the Company. Stockholders should not rely on the representations,
warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company. Moreover, information concerning the subject matter of the representations and warranties may change after the date
of the Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures.
The foregoing
description of the Private Placement and the Purchase Agreement, the Warrants, the Certificate of Designation, the Registration Rights Agreement, the Engagement Letter and the Support Agreement is qualified in its entirety by reference to the
Purchase Agreement, the form of Warrant, the form of Certificate of Designation, the form of Registration Rights Agreement, the Engagement Letter and the form of Support Agreement, which are filed hereto as Exhibits 10.1, 4.1, 3.1, 4.2, 10.2, and
10.3 respectively.